title: Herbimycin A induces G1 arrest through accumulation of p27(Kip1) in cyclin D1-overexpressing fibroblasts.
abstract: The ansamycin antibiotic herbimycin A is a potent tyrosine kinase inhibitor and reduces the growth rate of various types of mammalian cells. When quiescent Rat6 fibroblast cells were treated with herbimycin A, serum-induced expression of cyclin D1 was inhibited, and this was associated with inhibition of G1 phase progression. However, herbimycin A also inhibited serum-induced G1 progression in derivatives of the Rat6 fibroblast cell line that stably overexpress a human cyclin D1 cDNA (R6ccnD1#4 cells), without affecting the expression levels of G1 cyclins. We found that herbimycin A prevented serum-induced downregulation of the cyclin-dependent kinase inhibitor p27(Kip1), thereby leading to inactivation of the protein kinase activity of CDK2. These results suggest that herbimycin A inhibits a tyrosine kinase(s) that plays a role in degradation of the p27(Kop1) protein.
authors.affiliation: Department of Applied Chemistry, Faculty Science and Technology, Keio University, 3-14-1 Hiyoshi, Kohoku-ku, Yokohama, 223-8522, Japan. imoto@apple.keio.ac.jp
authors.forename: N
authors.initials: N
authors.lastname: Endo
authors.forename: E
authors.initials: E
authors.lastname: Tashiro
authors.forename: K
authors.initials: K
authors.lastname: Umezawa
authors.forename: M
authors.initials: M
authors.lastname: Kawada
authors.forename: Y
authors.initials: Y
authors.lastname: Uehara
authors.forename: Y
authors.initials: Y
authors.lastname: Doki
authors.forename: I B
authors.initials: IB
authors.lastname: Weinstein
authors.forename: M
authors.initials: M
authors.lastname: Imoto
mesh_terms: D000818:Animals; D016227:Benzoquinones; D042846:CDC2-CDC28 Kinases; D002453:Cell Cycle / Q000187:drug effects*; D018797:Cell Cycle Proteins; D002460:Cell Line; D016895:Culture Media, Serum-Free; D019938:Cyclin D1 / Q000235:genetics* / Q000502:physiology*; D051357:Cyclin-Dependent Kinase 2; D050760:Cyclin-Dependent Kinase Inhibitor p27; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000378:metabolism*; D005347:Fibroblasts; D016193:G1 Phase / Q000187:drug effects; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D047029:Lactams, Macrocyclic; D008869:Microtubule-Associated Proteins / Q000378:metabolism*; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D011809:Quinones / Q000494:pharmacology*; D051381:Rats; D011994:Recombinant Proteins / Q000378:metabolism; D017828:Rifabutin / Q000031:analogs & derivatives; D016196:S Phase / Q000187:drug effects; D014162:Transfection; D025521:Tumor Suppressor Proteins
chemical_list: D016227:Benzoquinones; C493962:Cdkn1b protein, rat; D018797:Cell Cycle Proteins; D016895:Culture Media, Serum-Free; D004791:Enzyme Inhibitors; D047029:Lactams, Macrocyclic; D008869:Microtubule-Associated Proteins; D011809:Quinones; D011994:Recombinant Proteins; D025521:Tumor Suppressor Proteins; D019938:Cyclin D1; D050760:Cyclin-Dependent Kinase Inhibitor p27; D017828:Rifabutin; C020754:herbimycin; D017346:Protein Serine-Threonine Kinases; D042846:CDC2-CDC28 Kinases; C495894:CDK2 protein, human; C495892:Cdk2 protein, rat; D051357:Cyclin-Dependent Kinase 2; D018844:Cyclin-Dependent Kinases